Kenvue Inc.
Rank #198ValueKVUE · NYSE · Consumer Defensive
Kenvue Inc. (KVUE) — Rank #198 by gross profitability (GP/assets 0.33) · ROE 13.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001944048 · all metrics point-in-time as of the filing date.
About
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Show moreShow less
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.
was incorporated in 2022 and is headquartered in Summit, New Jersey.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- January 3
- Website
- kenvue.com
Segments
A revenue-by-segment breakdown is not available for KVUE. This is expected for a single-reportable-segment filer with no product/service revenue disaggregation, or for a company whose filings predate SEC’s XBRL viewer.